Aytu BioScience (NASDAQ:AYTU) announces results
from a National Cancer Institute evaluation of the performance of its
COVID-19 IgG/IgM rapid antibody blood test. Results from a 110-sample
panel (30 confirmed positives, 80 confirmed negatives):
IgG sensitivity/specificity: 96.7%/97.5%.
IgM sensitivity/specificity: 100.0%/100.0%.
Combined sensitivity/specificity: 100.0%/97.5%.
The FDA OK’d the emergency use of the test on May 29.
https://seekingalpha.com/news/3581516-aytu-announces-performance-stats-on-covidminus-19-blood-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.